Evidence map›Paper›PMID 31570564›Full record

ReviewInfection and immunity2019

Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Mahmoud M Saleh, William A Petri

Open access · bronzeAbstract readReview
In one paragraph

Review in Infection and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026
    Review
  3. Phase variable colony morphotypes ofbioRxiv : the preprint server for biology · 2026
    Article
  4. The complete catalog of antimicrobial resistance secondary active transporters inComputational and structural biotechnology journal · 2024
    Article
  5. Microbiology (Reading, England) · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mahmoud M SalehDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
William A PetriDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA wap3g@virginia.edu.
University of Virginia Health System · US

Funding

Role of Type 2 Immunity in Innate Protection from C. difficileR01AI124214 · NIAID · UNIVERSITY OF VIRGINIA · PI William A Petri · 2016 to 2026
$5.4M
NIAID NIH HHS R01 AI124214
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adaptive ImmunityImmunity, InnateAnimalsClostridioides difficileClostridium InfectionsCytokinesHumansImmunologic FactorsMiceCytokinesImmunologic FactorsClostridioides difficileClostridium difficileIL-17AIL-22IL-23ILC3neutrophilsTh17type 3 immunity

Identifiers

PMID31570564
PMCPMC6921663
OpenAlexW2975065918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.